【摘要】 目的：观察消炎痛与ＩＦＮ联合应用治疗慢性乙型肝炎的疗效及副作用。方法：选择有传染性指标的慢性乙型肝炎患者４６例随机分为２组：试验组（消炎痛＋ＩＦＮ）２３例，开始每天肌注ｒＩＦＮα２ｂ３００万Ｕ，１０ｄ后改为隔日肌注３００万Ｕ，同时加用消炎痛肠溶片２５ｍｇｔｉｄ和一般保肝药物，疗程３个月；对照组２３例，除了不加用消炎痛外，其它治疗与试验组相同。ＨＢｓＡｇ、抗－ＨＢｓ、ＨＢｅＡｇ、抗－ＨＢｅ、抗－ＨＢｃ采用ＥＬＩＳＡ法，ＨＢＶ－ＤＮＡ用ＰＣＲ法检测。结果：试验组ＨＢｅＡｇ和ＨＢＶ－ＤＮＡ转阴率分别为７１．４％和４７．８％；而对照组分别为４３．６％和２８．６％，两项的转阴率虽以试验组为高，但差异尚未达到统计学意义（Ｐ＞０．０５）；试验组流感样反应明显轻于对照组（Ｐ＜０．０１）。结论：消炎痛联合ＩＦＮ治疗慢性乙型肝炎能明显减轻ＩＦＮ的“流感样”副反应，消炎痛是否能增强ＩＦＮ的抗病毒效应，尚有待进一步研究。更多还原

【Abstract】 Objective:To observe the effects of recombinant interferon α 2 b (rIFNα) combined with indomethacin (indo) on chronic hepatitis B. Methods: 46 patients with chronic hepatitis B (CHB) were randomly divided into two groups: rIFNα indo group (n=23) received rIFNα plus indo treatment,and control group (n=23) received only rIFNα.The course of treatment was three months. HBV markers and HBV DNA were determined by ELISA and PCR respectively.Results:At the end of treatment the clearance rates of serum HBeAg and HBV DNA were higher in rIFNα indo group than in control group (71.4% and 47.8% vs 43.6% and 28.6% respectively), though there was still no statistical difference ( P >0.05).rIFNα side effects such as high fever and “influenza like” symptoms obviously decreased in rIFNα indo group as compared with control group ( P <0.01). Conclusion:indo could significantly decrease the side effects of rIFNα treatment,but whether it could increase antiviral signals of rIFNα remains to be confirmed.更多还原